ALK Positive/alkpositive.org
Apr 22, 2025, 02:00
What if a drug approved for a type of leukemia could help treat ALK+ lung cancer? – ALK Positive Inc.
ALK Positive Inc. shared a post on LinkedIn:
“What if a drug approved for a type of leukemia could help treat ALK+ lung cancer?
This new ALK+ lung cancer trial at the University of Michigan explores gilteritinib, an FDA-approved leukemia drug, seeking to understand if it could be repurposed to tackle treatment resistance in ALK lung cancer. Read this powerful story shows how researchers, patient advocates, and pharma are partnering to bring an existing drug into a brand-new fight.
Read more. Led by UM Rogel Cancer Center, Astellas US and ALK Positive, Inc.
Inspired by global research. Driven by patient need.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 11, 2025, 15:24
May 11, 2025, 15:17
May 11, 2025, 15:01
May 11, 2025, 14:41
May 11, 2025, 14:35